S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:RGLS

Regulus Therapeutics Stock Forecast, Price & News

$1.30
+0.15 (+13.04 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.00
Now: $1.30
$1.30
50-Day Range
$1.15
MA: $1.45
$1.94
52-Week Range
$0.42
Now: $1.30
$1.97
Volume2.07 million shs
Average Volume2.09 million shs
Market Capitalization$50.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Regulus Therapeutics logo

Headlines

Regulus Announces Addition to Board of Directors
January 27, 2021 |  finance.yahoo.com
Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates
November 5, 2020 |  finance.yahoo.com
Regulus Therapeutics Inc
October 18, 2020 |  bloomberg.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300
Employees24
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.83 million
Book Value$0.95 per share

Profitability

Net Income$-18,590,000.00

Miscellaneous

Market Cap$50.91 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.94 out of 5 stars

Medical Sector

1067th out of 1,969 stocks

Pharmaceutical Preparations Industry

488th out of 771 stocks

Analyst Opinion: 1.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.30
+0.15 (+13.04 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

Is Regulus Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Regulus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RGLS, but not buy additional shares or sell existing shares.
View analyst ratings for Regulus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Regulus Therapeutics?

Wall Street analysts have given Regulus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regulus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Regulus Therapeutics?

Regulus Therapeutics saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 2,380,000 shares, an increase of 31.5% from the January 14th total of 1,810,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is currently 1.1 days.
View Regulus Therapeutics' Short Interest
.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Regulus Therapeutics
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) issued its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.17. The biopharmaceutical company had revenue of $5 million for the quarter, compared to the consensus estimate of $0.51 million.
View Regulus Therapeutics' earnings history
.

How has Regulus Therapeutics' stock price been impacted by COVID-19?

Regulus Therapeutics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGLS shares have increased by 116.7% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RGLS?

3 analysts have issued 12 month target prices for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $1.50. On average, they expect Regulus Therapeutics' stock price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 3.8%.
View analysts' price targets for Regulus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the following people:
  • Mr. Joseph P. Hagan M.B.A., Pres, CEO & Director (Age 52, Pay $1.4M)
  • Ms. Crispina Calsada, Chief Financial Officer (Age 51, Pay $355.16k)
  • Mr. Christopher Ray Aker J.D., Sr. VP. Gen. Counsel & Corp. Sec. (Age 60, Pay $575.3k)
  • Mr. Daniel J. Penksa, Controller & Principal Accounting Officer (Age 35)
  • Dr. Denis Drygin Ph.D., Chief Scientific Officer
  • Mr. Turner Jenkins, Sr. Director of Corp. Devel.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics CEO Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among Regulus Therapeutics' employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Regulus Therapeutics' key competitors?

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (1.28%), Renaissance Technologies LLC (1.15%), Grimes & Company Inc. (0.14%), GYL Financial Synergies LLC (0.13%) and BlackRock Inc. (0.13%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Daniel R Chevallard, Joseph P Hagan, Pascale Witz, Paul Edward Walker and Peter J Barris.
View institutional ownership trends for Regulus Therapeutics
.

Which major investors are selling Regulus Therapeutics stock?

RGLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have sold Regulus Therapeutics company stock in the last year include Christopher Ray Aker, and Joseph P Hagan.
View insider buying and selling activity for Regulus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Regulus Therapeutics stock?

RGLS stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Renaissance Technologies LLC, GYL Financial Synergies LLC, and Grimes & Company Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Joseph P Hagan, Pascale Witz, Paul Edward Walker, and Peter J Barris.
View insider buying and selling activity for Regulus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $1.30.

How much money does Regulus Therapeutics make?

Regulus Therapeutics has a market capitalization of $50.91 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-18,590,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does Regulus Therapeutics have?

Regulus Therapeutics employs 24 workers across the globe.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is www.regulusrx.com.

Where are Regulus Therapeutics' headquarters?

Regulus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.